The ongoing review of breast services at County Durham and Darlington NHS Foundation Trust (CDDFT) has caused serious concern for many people. It is examining the care of thousands of patients treated by the trust’s breast service, many of them for cancer. So far, it has found that 20 women had mastectomies they did not need, a loss no apology can undo.

For anyone affected, this is likely to be a worrying and uncertain time. Our guide explains what has happened, what the independent investigations have found so far, and what options are available to you.

What timeframe is under review?

The breast surgery lookback review began in April 2025. It initially examined cases from January 2023 to February 2025. The review is being extended to cover cases before 2023, one year at a time, potentially as far back as 2015. Patients will be contacted if concerns about their care are identified. Anyone worried about what happened to them can contact the Trust to discuss their treatment.

Does the review only cover Mr Amir Bhatti’s patients?

The review covers patients treated across CDDFT’s entire breast service, not only those treated by Mr Amir Bhatti, the trust’s former clinical lead for breast surgery. Much of the coverage about inadequate treatment has focused on Mr. Bhatti, but he is one of several clinicians whose care is being examined. If you have any concerns about what happened to you, it is worth raising them.

I was treated privately at Spire Washington Hospital. Am I covered?

Private patients are not part of CDDFT’s review, but Spire is running its own patient recall. Mr Amir Bhatti treated private patients at Spire Washington Hospital, but no longer has practising privileges at any Spire hospital. Our CDDFT breast care review page explains how to contact Spire, and how we can help if you have concerns about private treatment.

Is Amir Bhatti still treating patients?

Mr Bhatti was CDDFT’s clinical lead for breast services from 2013 to 2024. He was restricted from patient care in February 2025, and in May 2026 the High Court refused his application to have those restrictions lifted. He remains employed by the trust while its investigation continues. He is one of several clinicians whose care is being examined.

How and when will I be contacted?

As part of CDDFT’s ongoing investigation, patients are being contacted when concerns have been identified about their care. Others are receiving reassurance that their treatment was appropriate, following a review.

You do not need to wait to be contacted. CDDFT has said that anyone with concerns about their breast care can speak to the hospital team on:

Telephone: 0191 333 2126
Email: cddft.breastservices@nhs.net

Can I opt out of being contacted?

Patients identified by the review can choose not to be contacted. Opting out of contact doesn’t stop you seeking independent advice later, although time limits still apply.

What happened with CDDFT breast care?

Chief nurse Gill Hunt told the CDDFT board on 24 September 2026 that concerns about breast care were first raised in 2015, after changes to the service and the loss of breast surgical trainee posts. She said that the Northern Cancer Alliance, the Care Quality Commission and NHS England had raised multiple issues in the years since. These included treatment “not aligned to best practice”, excessive surgery and delayed diagnosis.

So far, 538 cases have been reviewed. Of these, 321 involved some form of avoidable harm, including one death.

At the extraordinary meeting of the CDDFT board held in Durham, board chair Alison Marshall said: “I would like to offer a sincere apology to all the women and their families who have been affected by the failings in our breast services.” She said they could “not turn back the clock” but would be “open, honest and transparent” about the failings.

Following that board meeting, it was announced that CDDFT was extending the lookback review one year at a time, potentially as far back as 2015. This could bring up to 4,500 additional patients into the review.

Which hospitals are involved? 

The review covers care given by CDDFT’s breast service, including at University Hospital of North Durham and Darlington Memorial Hospital. Many patients were also referred to external two-week-wait clinics run on the trust’s behalf, and care at those clinics forms part of the review.

How many women had an unnecessary mastectomy?

CDDFT has confirmed that 20 women had mastectomies they did not need. Of the 538 cases reviewed so far (from 1,472 in the first review period), the 321 cases involving harm break down as:

  • 242 cases of minor harm.
  • 59 cases of moderate harm.
  • 19 cases of severe harm.
  • One patient who died.

A further 20 cases involved a delayed diagnosis.

Why did CDDFT’s breast service fail? 

Independent reviews found that an outsourcing deal created a financial incentive to operate. The BBC reported that CDDFT paid nearly £6 million over six years to breast diagnostic clinics and surgery companies run privately by Mr Bhatti. The trust’s chief executive has said the arrangement was not properly managed, and outsourcing for breast cancer services has since ended.

What did the Royal College of Surgeons find?

A Northern Cancer Alliance review of differences in treatment identified breast surgery outcomes at CDDFT that differed from those at other trusts. This led to a Northern Cancer Alliance peer review, a Getting It Right First Time review in 2024 and an invited review by the Royal College of Surgeons.

The Royal College of Surgeons review took place in early 2025 and reported its findings in April 2025. The review identified several serious concerns, including:

  • Variations in surgical practice compared with accepted national standards.
  • Concerns about clinical decision-making and the arrangements for overseeing care.
  • Weaknesses in how healthcare professionals from different specialities worked together.
  • The continued use of techniques that were no longer considered best practice.
  • Higher rates of mastectomy and lower rates of breast reconstruction than nationally expected.
  • Questions about whether some patients had undergone more extensive surgery than was clinically necessary.

CDDFT also accepted that opportunities to identify and address concerns may have been missed over several years.

The independent governance review found failures in oversight and highlighted the need for stronger leadership, better oversight of clinical care and stronger patient safety systems.

What happens next?

The lookback review is ongoing and is likely to take several years to complete. CDDFT has said that it is continuing to examine patients’ medical records with support from external experts and is contacting patients when concerns are identified.

CDDFT has acknowledged serious and long-standing failings in the breast care provided to patients.

The review team will finish reviewing cases from each year before deciding whether to examine patients seen in the previous year. That decision will not depend on a single figure. The team will consider:

  • the number and seriousness of any concerns or harm identified.
  • whether CDDFT is seeing recurring themes or patterns.
  • what patients and families are telling the review team.
  • whether looking further back is likely to identify more people who need information, support or clinical follow-up.
  • advice from independent breast specialists.

Alongside the patient review process, a group has been set up to monitor improvements and ensure that recommendations from the reviews are put into practice.

For many patients, the immediate priority will be understanding whether their care was affected and whether any further treatment, monitoring or investigations are required.

When will my year of treatment be reviewed?

Once cases from January 2023 to February 2025 are complete, the review will move to patients treated in 2022 and then work backwards a year at a time towards 2015. CDDFT estimates this could take around five years. You do not have to wait for your year. The trust has already reviewed the care of 640 former patients who came forward through its dedicated helpline.

What support is available while I wait?

CDDFT is offering psychological support to patients affected by the review, and its helpline is open to anyone with concerns, whenever they were treated. Your GP can help if you have new symptoms or worries about your health. Breast Cancer Now offers free, confidential support from specialist nurses.

How do I get a copy of my medical records?

You can request your medical records from CDDFT by making a subject access request. This is usually free, and the trust should normally respond within one month. Ask for your complete records, including clinic letters, scan and pathology reports, and notes from multidisciplinary team meetings. With your agreement, we can help by requesting and interpreting them on your behalf.

I was told my treatment was fine — Should I still be concerned?

A letter of reassurance means the review has not found a problem with your care, and for many patients that will be the end of the matter. However, if you still have questions, for example about why you were not offered reconstruction or breast-conserving surgery, an independent review of your records by a medical expert can give you a second opinion.

Could there be grounds for a medical negligence claim?

Being recalled for a review does not necessarily mean that you have grounds for a medical negligence claim. If you have concerns about the breast care you received at CDDFT, it is reasonable to seek independent legal advice as early as possible.

Our specialist medical negligence team can investigate whether there is evidence that your treatment fell below an acceptable standard and whether that caused you avoidable harm. Where the evidence supports a claim, we can pursue compensation on your behalf and seek explanations and accountability from those responsible.

Potential issues already identified at CDDFT include:

  • Delayed diagnosis of breast cancer.
  • Failure to offer appropriate treatment options.
  • Unnecessary surgery.
  • More extensive surgery than was clinically required.
  • Failure to follow recognised clinical guidelines.
  • Inadequate review of treatment decisions by healthcare professionals from different specialties.
  • Delays in treatment resulting in disease progression or a poorer outcome.

We understand the devastating impact that concerns about treatment and surgery can have on patients and their families. Many people come to us not only seeking compensation but also wanting answers about what happened.

Is there a time limit and, if so, does the review pause it?

Medical negligence claims usually have to be started within three years of your treatment, or within three years of when you first knew, or could reasonably have known, that something had gone wrong. The review does not pause this deadline, so waiting for a letter could cost you time. If someone close to you has died, different time limits may apply.

Our experience in cancer negligence claims

CL Medilaw has extensive experience representing patients and families affected by failures in cancer diagnosis and treatment. We regularly investigate cases involving:

  • Delayed diagnosis of breast cancer.
  • Failures to refer under the urgent suspected cancer pathway.
  • Misinterpretation of mammograms, scans, and pathology results.
  • Failures to provide appropriate treatment or surgery.
  • Inadequate follow-up and monitoring after treatment.

If you are concerned that delays, misdiagnosis or failures in treatment may have affected the care you or a loved one received through the CDDFT breast service, our specialist team can help you understand your options. We provide clear advice, compassionate support and robust representation, helping patients and families seek answers, accountability and, where appropriate, compensation.

Contact us today to speak with a specialist about your experience.

Get in Touch

Related Posts